180 Life Sciences Corp. Files 8-K Report
Ticker: FRMM · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1690080
Sentiment: neutral
Topics: corporate-filing, financials, other-events
Related Tickers: ATNF
TL;DR
180 Life Sciences filed an 8-K on 7/30/24 covering other events and financials.
AI Summary
On July 30, 2024, 180 Life Sciences Corp. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, formerly known as KBL Merger Corp. IV, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides an update on the company's corporate events and financial reporting, which is crucial for investors to stay informed about the company's status and any material developments.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Numbers
- 001-38105 — Commission File Number (Identifies the company's filing with the SEC.)
- 90-1890354 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant
- KBL Merger Corp. IV (company) — Former Company Name
- July 30, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Palo Alto, CA (location) — Business Address
FAQ
What specific "Other Events" are detailed in this 8-K filing?
The provided text does not specify the 'Other Events'; it only lists 'Other Events' as an item information category.
What is the SIC code for 180 Life Sciences Corp.?
The Standard Industrial Classification (SIC) code for 180 Life Sciences Corp. is 2834, which corresponds to Pharmaceutical Preparations.
When did 180 Life Sciences Corp. change its name from KBL Merger Corp. IV?
The date of the name change from KBL Merger Corp. IV to 180 Life Sciences Corp. was November 15, 2016.
What is the business address of 180 Life Sciences Corp.?
The business address of 180 Life Sciences Corp. is 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA 94306.
What is the fiscal year end for 180 Life Sciences Corp.?
The fiscal year end for 180 Life Sciences Corp. is December 31.
Filing Stats: 471 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-07-30 08:00:33
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Mar
Filing Documents
- ea0210232-8k_180lifesci.htm (8-K) — 29KB
- ea021023201ex99-1_180life.htm (EX-99.1) — 21KB
- 0001013762-24-002270.txt ( ) — 274KB
- atnf-20240730.xsd (EX-101.SCH) — 4KB
- atnf-20240730_def.xml (EX-101.DEF) — 26KB
- atnf-20240730_lab.xml (EX-101.LAB) — 36KB
- atnf-20240730_pre.xml (EX-101.PRE) — 25KB
- ea0210232-8k_180lifesci_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On July 30, 2024, 180 Life Sciences Corp. (the " Company ") filed a press release disclosing the topline results of a clinical pharmacology study testing a new solid formulation of cannabidiol (CBD) with enhanced oral uptake. A copy of the press release is included herewith as Exhibit 99.1 and the information in the press release is incorporated by reference into this Item 8.01 in its entirety by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated July 30, 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 30, 2024 180 LIFE SCIENCES CORP. By: /s/ Blair Jordan Name: Blair Jordan Title: Interim Chief Executive Officer 2